MX370065B - Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. - Google Patents
Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.Info
- Publication number
- MX370065B MX370065B MX2017010666A MX2017010666A MX370065B MX 370065 B MX370065 B MX 370065B MX 2017010666 A MX2017010666 A MX 2017010666A MX 2017010666 A MX2017010666 A MX 2017010666A MX 370065 B MX370065 B MX 370065B
- Authority
- MX
- Mexico
- Prior art keywords
- hyloxazole
- fluorobiphenyl
- carbonyl
- chloro
- hydroxy
- Prior art date
Links
- RRCIEZCEOIRHEB-VQIMIIECSA-N (2R,4R)-5-[4-(5-chloro-2-fluorophenyl)phenyl]-2-hydroxy-4-[(5-methyl-1,3-oxazole-2-carbonyl)amino]pentanoic acid Chemical compound ClC=1C=CC(=C(C=1)C1=CC=C(C=C1)C[C@H](C[C@H](C(=O)O)O)NC(=O)C=1OC(=CN=1)C)F RRCIEZCEOIRHEB-VQIMIIECSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118067P | 2015-02-19 | 2015-02-19 | |
| PCT/US2016/017699 WO2016133803A1 (en) | 2015-02-19 | 2016-02-12 | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010666A MX2017010666A (es) | 2017-11-16 |
| MX370065B true MX370065B (es) | 2019-11-29 |
Family
ID=55456914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010666A MX370065B (es) | 2015-02-19 | 2016-02-12 | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9533962B2 (enExample) |
| EP (1) | EP3259255B1 (enExample) |
| JP (1) | JP6714009B2 (enExample) |
| KR (1) | KR102573351B1 (enExample) |
| CN (1) | CN107250119B (enExample) |
| AU (1) | AU2016220348B2 (enExample) |
| BR (1) | BR112017017783A2 (enExample) |
| CA (1) | CA2975269C (enExample) |
| CO (1) | CO2017008426A2 (enExample) |
| CY (1) | CY1123728T1 (enExample) |
| DK (1) | DK3259255T3 (enExample) |
| ES (1) | ES2857101T3 (enExample) |
| HR (1) | HRP20210040T1 (enExample) |
| HU (1) | HUE052732T2 (enExample) |
| IL (1) | IL253759B (enExample) |
| LT (1) | LT3259255T (enExample) |
| MX (1) | MX370065B (enExample) |
| MY (1) | MY191183A (enExample) |
| PH (1) | PH12017501444A1 (enExample) |
| PL (1) | PL3259255T3 (enExample) |
| PT (1) | PT3259255T (enExample) |
| RS (1) | RS61325B1 (enExample) |
| RU (1) | RU2715241C2 (enExample) |
| SG (1) | SG11201706662YA (enExample) |
| SI (1) | SI3259255T1 (enExample) |
| SM (1) | SMT202100028T1 (enExample) |
| TW (1) | TWI707846B (enExample) |
| WO (1) | WO2016133803A1 (enExample) |
| ZA (1) | ZA201705487B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55967B1 (sr) * | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| SG11201706662YA (en) | 2015-02-19 | 2017-09-28 | Theravance Biopharma R&D Ip Llc | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
| KR102238177B1 (ko) | 2017-09-15 | 2021-04-07 | 주식회사 엘지화학 | 전지셀 및 전극 리드 제조방법 |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| HRP20240534T1 (hr) * | 2019-07-03 | 2024-07-05 | Merck Patent Gmbh | Postupak za proizvodnju 3,5-difluoro-benzilamida (s)-3-hidroksi-l-(lh-indol-5-il)-2-okso-pirolidin-3-karboksilne kiseline |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| CN101631765B (zh) | 2007-01-12 | 2014-10-01 | 诺华股份有限公司 | 用于制备5-联苯基-4-氨基-2-甲基戊酸的方法 |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
| PL2435409T3 (pl) * | 2009-05-28 | 2015-01-30 | Novartis Ag | Podstawione pochodne aminopropionowe jako inhibitory neprylizyny |
| CA2763565A1 (en) * | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| WO2011011232A1 (en) * | 2009-07-22 | 2011-01-27 | Theravance, Inc. | Dual-acting oxazole antihypertensive agents |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| WO2011088797A1 (en) | 2010-01-22 | 2011-07-28 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| ES2548887T3 (es) | 2010-12-15 | 2015-10-21 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
| NZ610983A (en) | 2010-12-15 | 2014-10-31 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
| WO2012154249A1 (en) | 2011-02-17 | 2012-11-15 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
| KR101854874B1 (ko) | 2011-02-17 | 2018-05-04 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프릴리신 억제제로서 치환된 아미노부티릭 유도체 |
| CN103748070B (zh) | 2011-05-31 | 2015-06-24 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| EP2714662B1 (en) | 2011-05-31 | 2017-10-11 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| CN103582630B (zh) | 2011-05-31 | 2016-08-17 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| US9045443B2 (en) | 2012-05-31 | 2015-06-02 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
| CA2873328A1 (en) | 2012-06-08 | 2013-12-12 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| RS55967B1 (sr) | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| HRP20170088T1 (hr) | 2012-08-08 | 2017-03-24 | Theravance Biopharma R&D Ip, Llc | Inhibitori neprilizina |
| DK2964616T3 (en) | 2013-03-05 | 2017-08-28 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| SG11201606057PA (en) * | 2014-01-30 | 2016-08-30 | Theravance Biopharma R&D Ip Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
| BR112017017317B1 (pt) | 2015-02-11 | 2023-02-14 | Theravance Biopharma R&D Ip, Llc | Composto, forma cristalina, composições farmacêuticas, forma de dosagem oral ou intravenosa, processos para a preparação do composto ou da forma cristalina e uso |
| SG11201706662YA (en) | 2015-02-19 | 2017-09-28 | Theravance Biopharma R&D Ip Llc | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
-
2016
- 2016-02-12 SG SG11201706662YA patent/SG11201706662YA/en unknown
- 2016-02-12 MX MX2017010666A patent/MX370065B/es active IP Right Grant
- 2016-02-12 LT LTEP16708268.4T patent/LT3259255T/lt unknown
- 2016-02-12 RU RU2017132430A patent/RU2715241C2/ru active
- 2016-02-12 HU HUE16708268A patent/HUE052732T2/hu unknown
- 2016-02-12 DK DK16708268.4T patent/DK3259255T3/da active
- 2016-02-12 EP EP16708268.4A patent/EP3259255B1/en active Active
- 2016-02-12 WO PCT/US2016/017699 patent/WO2016133803A1/en not_active Ceased
- 2016-02-12 BR BR112017017783-8A patent/BR112017017783A2/pt not_active Application Discontinuation
- 2016-02-12 CA CA2975269A patent/CA2975269C/en active Active
- 2016-02-12 CN CN201680011254.0A patent/CN107250119B/zh active Active
- 2016-02-12 HR HRP20210040TT patent/HRP20210040T1/hr unknown
- 2016-02-12 MY MYPI2017702772A patent/MY191183A/en unknown
- 2016-02-12 RS RS20210057A patent/RS61325B1/sr unknown
- 2016-02-12 SI SI201631051T patent/SI3259255T1/sl unknown
- 2016-02-12 KR KR1020177026454A patent/KR102573351B1/ko active Active
- 2016-02-12 ES ES16708268T patent/ES2857101T3/es active Active
- 2016-02-12 PL PL16708268T patent/PL3259255T3/pl unknown
- 2016-02-12 JP JP2017543772A patent/JP6714009B2/ja active Active
- 2016-02-12 PT PT167082684T patent/PT3259255T/pt unknown
- 2016-02-12 SM SM20210028T patent/SMT202100028T1/it unknown
- 2016-02-12 AU AU2016220348A patent/AU2016220348B2/en not_active Ceased
- 2016-02-12 US US15/042,391 patent/US9533962B2/en active Active
- 2016-02-19 TW TW105104991A patent/TWI707846B/zh active
- 2016-11-21 US US15/357,269 patent/US9872855B2/en active Active
-
2017
- 2017-07-31 IL IL253759A patent/IL253759B/en active IP Right Grant
- 2017-08-10 PH PH12017501444A patent/PH12017501444A1/en unknown
- 2017-08-14 ZA ZA2017/05487A patent/ZA201705487B/en unknown
- 2017-08-18 CO CONC2017/0008426A patent/CO2017008426A2/es unknown
- 2017-12-14 US US15/841,799 patent/US10172834B2/en active Active
-
2018
- 2018-12-03 US US16/207,501 patent/US10548879B2/en active Active
-
2019
- 2019-12-16 US US16/715,722 patent/US11033533B2/en not_active Expired - Fee Related
-
2021
- 2021-01-20 CY CY20211100045T patent/CY1123728T1/el unknown
- 2021-05-14 US US17/302,877 patent/US11642332B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| WO2012168885A3 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| HK1257171A1 (zh) | 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法 | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| PH12018501876A1 (en) | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| ZA201801839B (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| HK1243399A1 (en) | (2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα | |
| PH12018500946A1 (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| HK1231074A1 (en) | Neprilysin inhibitors | |
| HK1233185A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| HK1233909A1 (en) | Pharmaceutical compositions of therapeutically active compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |